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Abstract. The transport of commercially available macrolide antibiotics erythromycin, clarithromycin, 
roxithromycin, azithromycin, and telithromycin was studied by PAMPA, a model of passive diffusion, 
and by two models of active transport, Caco-2 and MDCKII-hMDR1. An involvement of efflux pump  
P-glycoprotein (P-gp) in macrolide transport was also examined. Generally, in Caco-2 and MDCKII-hMDR1 
assays without P-gp inhibition, a significantly lower apparent permeability (Papp) in apical-to-basolateral 
(AB) than basolateral-to-apical (BA) direction was observed [efflux ratio, Pappratio(BA/AB) > 4.2]. Upon  
P-gp inhibition, Papp(AB) was increased and Papp(BA) was decreased. The observed Papp values, their  
efflux ratios, as well as a significant decrease in efflux ratios caused by P-gp inhibition (> 50 %) qualify 
all tested macrolides as P-gp substrates. Results obtained with PAMPA suggest that this assay is not a me-
thod of choice for screening of macrolide permeability due to the lack of P-gp efflux pump and/or other 
transporters potentially involved in macrolide transport. 
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INTRODUCTION 
The intestinal epithelium permeability is recognized as a 
critical feature that determines the rate and extent of 
human absorption and at last, the bioavailability of 
drugs. Commonly used in vitro methods to assess intes-
tinal permeability in early drug discovery include: paral-
lel artificial membrane permeability assay (PAMPA), 
Caco-2 and Madin-Darby canine kidney (MDCK) cell 
assays.1–3 PAMPA represents a rapid, low-cost alterna-
tive to cellular models for early ADME screening of 
new chemical entities, where a mammalian membrane is 
mimicked by various filter-supported lipid membrane 
systems.4–7 However, due to the lack of facilitators of 
active transport, only passive diffusion is assessed by 
PAMPA. Alternatively, cellular models offer several 
advantages over PAMPA due to over expression of the 
transporter of interest, precise control of experimental 
conditions, and, usually, the lack of other confounding 
physiological processes. Originally derived from human 
colon adenocarcinoma, Caco-2 cells express transporter 
proteins, efflux proteins [apically localized P-glyco-
protein (P-gp) efflux pump],8–10 and Phase II conjuga-
tion enzymes responsible for metabolic transformation 
of test substances. Consequently, Caco-2 cells are the 
most frequently used in vitro tool for prediction of drug 
permeability and absorption potential,11,12 as they have 
shown to be predictive of transcellular-based absorption 
including passive diffusion, active transport, efflux and 
paracellular transport.13,14 As an alternative to Caco-2 
cells, MDCK cells with over expressed human multi-
drug-resistant gene (hMDR), MDCKII-hMDR1, have 
become the method of choice to study bidirectional 
transport of compounds and to evaluate the influence of 
P-gp.15–17 This is due to the significantly shorter culture 
time (3–5 vs. 21 days) which reduces cost and increases 
throughput, low expression levels of transporter proteins 
and low metabolic activity. In spite of their moderate 
bioavailabilities in humans,18,19 some macrolide anti-
biotics20,21 are identified to be substrates/inhibitors for 
the main drug efflux pump P-gp,22–26 which is known to 
restrict intestinal permeation. Studies in rats and humans 
have shown that P-gp inhibition with macrolides in 
addition to the cytochrome P450 3A4 (CYP3A4) inhi-
bition,27 can cause severe drug-drug interactions affect-
ing oral bioavailability of co-administered drugs.28–30 
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Recent papers indicate that uptake transporter function 
of organic anion transporting polypeptide (OATP) fami-
ly should be considered as an additional potential me-
chanism of drug-drug interaction with macrolides.31,32 
In the present study, five macrolide antibiotics 
(erythromycin, clarithromycin, roxithromycin, azithro-
mycin, and telithromycin) were characterized and com-
pared according to their permeability through biological 
membranes (Figure 1). Their permeabilities were stu-
died using three different in vitro methods: PAMPA and 
cellular based Caco-2 and MDCKII-hMDR1 assays, 
with and without known P-gp inhibitors, in order to 
evaluate their applicability to macrolides. 
 
EXPERIMENTAL 
Materials 
Clarithromycin, azithromycin (Pliva, Zagreb, Croatia), 
telithromycin (Sanofi-aventis, Paris, France), and testo-
sterone (Steraloids, Wilton, NH, USA) were used in this 
study. Erythromycin, roxithromycin, verapamil, propa-
nolol hydrochloride, warfarin, dimethyl sulfoxide 
(DMSO), phosphate-buffered saline (PBS), Hank's 
balanced salt solution (HBSS), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), lucifer yellow, 
acetonitrile (all from Sigma-Aldrich, Munich, Germa-
ny), lecithin [Lipoid E100 (Lipoid, Ludwigshafen, 
Germany)], and n-dodecane (Merck, Darmstadt, Ger-
many) were purchased. Amprenavir and 9,10-dihydro- 
5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-
2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide 
(GF120918A) were acquired from our compound repo-
sitory (GlaxoSmithKline, Stevenage, UK). Dulbecco's 
Modified Eagles medium (DMEM), fetal bovine serum 
(FBS), glutamax, nonessential amino acids (NEAA), 
penicillin-streptomycin, Fungizone (amphotericin B), 
trypsin-EDTA, and Dulbecco's Phosphate Buffered 
Saline (DPBS) were purchased from Gibco Life Tech-
nologies (Invitrogen, Carlsbad, CA, USA). Caco-2 cells 
were obtained at passage 47 (European Collection of 
Cell Cultures, Health Protection Agency Culture Collec-
tions, Salisbury, UK). MDCKII-hMDR1 cells were 
obtained at passage 30 (Netherlands Cancer Institute, 
Amsterdam, Netherlands). 
 
Parallel Artificial Membrane Permeability Assays 
(PAMPA) 
DMSO stock solution of tested substance was diluted 
with PBS buffer (10 mmol dm–3, pH = 7.4) to a final 
concentration of 500 µmol dm–3 with 5 % (volume frac-
tion, φ) of DMSO. The artificial membrane was pre-
pared using a 1 % (φ) solution of lecithin in n-dodecane 
and sonicated using a probe to ensure complete dissolu-
tion. Avoiding pipette tip contact with the membrane,  
5 µl of the lecithin/n-dodecane mixture was pipetted 
into each donor plate well (MultiScreen-IP PAMPA 
assay plate, Millipore, Billerica, MA, USA). Immediate-
ly after application of the artificial membrane, 150 µl of 
macrolide-containing donor solution was added to each 
well of the donor plate. A volume of 300 µl of buffer  
[5 % (φ) DMSO in 10 mmol dm–3 PBS, pH = 7.4] was 
added to each acceptor plate well (PTFE Acceptor plate, 
Millipore, Billerica, MA, USA). The macrolide-filled 
donor plate was then placed into the acceptor plate to 
create a “sandwich”, making sure the bottom of the 
membrane is in contact with the buffer. Standard con-
trols, used in the assays were warfarin (500 µmol dm–3) 
and testosterone (100 µmol dm–3) as markers of low and 
high permeability, respectively. The plate was incubated 
at room temperature (≈ 23 °C) for 3 and 24 h with a 
medium agitation. After incubation, macrolide concen-
trations in donor and acceptor plates were determined 
by LC-MS/MS method. The permeability studies were 
performed in duplicate for all tested substances, macro-
lides and standard controls, and the apparent permeabili-
ty Papp in [nm s–1] was calculated16 according to equa-
tion 
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and VD and VA are donor (D) and acceptor (A) solution 
volumes [cm3], respectively; area is active surface area 
of the membrane (i.e., area = 0.24 cm2 for the  
membrane in assay plate); t is incubation time [s];  
[substance]A,End is concentration [µmol dm–3] of tested 
substance in the acceptor compartment at the comple-
tion of the assay; and [substance]eq is concentration  
of tested substance at theoretical equilibrium (i.e.,  
 
Figure 1. Macrolides used in this study. 
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[substance]eq = 166 µM for the substances with initial 
concentration of 500 µmol dm–3).33 
 
Caco-2 Assay 
Caco-2 cells were cultured34 under controlled atmos-
phere (37 °C, 95 % air, 5 % CO2, 90 % relative humidi-
ty), seeded in plastic flasks and maintained with com-
plete medium [DMEM with glucose (4500 mg mL–1),  
10 % (φ) FBS, 1 % (φ) glutamax, 1 % (φ) NEAA, 1 % 
(φ) streptoycin (100 μg mL–1), and 1 % (φ) Fungizone 
(amphotericin B)]. Culture medium was changed every 
2 days and cultures were split (1:3 to 1:6) every 5 days 
when they reached 85–90 % confluence, using 0.05 % 
(φ) trypsin-EDTA. For transport studies, following 
equilibration with the culture medium for 2 h in CO2 
incubator, Caco-2 cells at passages 54–57 were seeded 
onto collagen coated 6-well polycarbonate Costar 
Transwell filter inserts (Corning, New York, NY, USA) 
in culture medium at the density of 2×105 cells per mL. 
The medium was changed the day after the seeding and 
every other day (or three times per week) and Caco-2 
cells were cultured on the filters for 20 to 22 days. On 
the day of the transport experiment, the culture medium 
was changed and 2 h thereafter the integrity of the cell 
monolayers was estimated microscopically and by mea-
suring transepithelial electrical resistance (TEER) by 
epithelial voltmeter Millicell-ERS (Millipore, Billerica, 
MA, USA), before and after the experiment. After re-
moving the culture medium, the monolayers were incu-
bated in the transport medium, for 2 h. 
Propanolol hydrochloride, a marker of high per-
meability and transcellular transport, was used as a 
control in the assay, dissolved in DMSO (10 mg mL–1) 
and diluted to a final concentration of 100 μmol dm–3 
using HBSS containing 12 mmol dm–3 HEPES adjusted 
at pH = 7.4 for preparation of transport medium. All 
tested substances were dissolved in DMSO (30 mmol 
dm–3 stock solutions) and later diluted with transport 
medium to a final concentration of 50 μmol dm–3. Each 
substance was tested in triplicate in both directions 
[apical-to-basolateral (AB) and basolateral-to-apical 
(BA)] and in the presence and absence of verapamil, a 
P-gp inhibitor (50 μmol dm–3). The amount of DMSO 
applied to the cells did not exceed 1 % (φ). For AB 
transport studies, the medium was removed from mono-
layers and the inserts were transferred to the new 6-well 
plate. Each well contained prewarmed transport medium 
(2.6 mL, 37 °C) in the lower compartment. Prewarmed 
solutions of tested substances (1.5 mL, 37 °C) were add-
ed to the upper compartments. For BA transport studies, 
prewarmed tested substances were added into the lower 
compartments (2.6 mL, 37 °C) and prewarmed transport 
medium was filled into the upper compartments (1.5 mL, 
37 °C). In AB and BA bidirectional studies, samples 
(100 μL) were taken at 0, 45, 90 and 135 min from the 
acceptor compartments and immediately replenished 
with the same volume of the transport medium. From 
the donor compartments, aliquots (20 μL) were taken at 
the beginning of the experiment (zero point) and at the 
end of the experiment (135 min). During transport expe-
riment, the plates were incubated at 37 °C and shaken at 
55 rpm. In addition, analogue experiments with pH 
gradient with pH = 6.5 and 7.4 in apical and basolateral 
compartments, respectively, were done for all tested 
substances. The concentrations of substances in the 
collected samples from donor and acceptor wells were 
determined by LC-MS/MS. The apparent permeability 
Papp in [nm s–1] was calculated according to the equation 
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where dQ/dt is the linear appearance rate obtained from 
the profile of the transported amount of the substrate 
against the time [μg s–1]; c0 is a measured initial concen-
tration in donor compartment [μg mL–1]; and area is the 
membrane surface area of cell monolayer (i.e., area = 
4.71 cm2 for 6-well plate). The ratio between Papp values 
in both transport studies (AB and BA) was calculated 
according to the expression 
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Mass balance MB was calculated by equation 
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where m represents mass of tested substance in donor 
(D) and acceptor (A) compartments at t = 0 min and at 
the end of transport assay (End) and all values above  
80 % were acceptable. 
 
MDCKII-hMDR1 Assay 
MDCKII-hMDR1 cells were grown in controlled  
atmosphere (37 °C, 95 % air, 5 % CO2, 90 % relative 
humidity) in DMEM with 10 % (φ) FBS, 1 % (φ) of 
glutamax I, 1 % (φ) of penicillin (100 U mL–1) - strep-
tomycin (100 μg mL–1) and 1 % (φ) of Fungizone (am-
photericin B) in cell culture flasks. Culture medium was 
changed every 2 days and cultures were split (1:3 to 1:6) 
every 5 days when they reached 85–90 % confluence, 
using 0.05 % (φ) trypsin-EDTA. Cells were prepared for 
transport studies by pre-incubation of 24-well cell cul-
ture inserts (Millipore, Billerica, MA, USA) with cul-
ture medium (1 h, 37 °C) and then seeded in a concen-
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tration of 0.3×106 cells per mL. The cells were fed with 
fresh medium 24 h post seeding and cultured to conflu-
ence for 3 days before use. On the day of experiment, 2 
h after feeding with the appropriate medium, the cell 
monolayers were washed and equilibrated with transport 
medium (DPBS, pH = 7.4) for 30 min (37 °C, 95 % 
humidity). Test substance solution consisted of test 
substance (5 μmol dm–3) in transport medium containing 
lucifer yellow (100 μmol dm–3) and 1 % (φ) DMSO. 
Transport assays were conducted using 400 and 800 μL 
of apical and basolateral solution, respectively, i.e., for 
AB study 400 μL of test substance solution was added 
to upper compartment and 800 μL of transport medium 
in the lower compartment. Monolayers were incubated 
with the dose solution for 90 min at 37 °C under gentle 
agitation. Apical and basolateral compartments were sam-
pled at the end of the transport experiment and the tested 
substance concentrations in both compartments were  
determined by LC-MS/MS. Each substance was tested 
three times in duplicate in both directions (AB and BA) 
and in the presence and absence of GF120918A (2 μmol 
dm–3), a specific P-gp inhibitor. Amprenavir (0.5 μmol 
dm–3) was used as a positive control in the assay. Like 
in Caco-2 assay, Papp in both directions (AB and BA), 
and Pappratio for all tested substances and amprenavir 
with and without GF120918A were determined using 
the same equations [3] and [4]. Mass balance was calcu-
lated using expression [5] and all values in range of  
80–120 % were acceptable. Lucifer yellow, a fluores-
cent marker for the paracellular pathway, was used as an 
internal control in every monolayer to verify tight junc-
tion integrity during the assay. Cell monolayers with 
lucifer yellow Papp > 30 nm s–1 were discarded. 
 
LC-MS/MS Analysis 
The LC-MS/MS system consisted of an Agilent 1100 
LC Binary Pump (Agilent Technologies, Waldbronn, 
Germany) with CTC Analytics HTS Pal autosampler 
(CTC Analytics, Zwingen, Switzerland) and a SCIEX 
API2000 or API3000 triple quadrupole mass spectrome-
ter (Applied Biosystems, Foster City, CA, USA). 
Chromatographic separation was performed using a 
Phenomenex C18 guard column and Phenomenex 
C18(2) (50×2.0 mm, 3 µm) column (Phenomenex, Tor-
rance, CA, USA) for gradient method with acetoni-
trile/water (both acidified with 0.1 % (φ) formic acid) as 
mobile phase, with flow rate of 0.3 mL min–1 at room 
temperature, and with injection volume of 5 µl. Tested 
substances were analysed using positive-ion mode with 
the following multiple reaction monitoring (MRM) 
transitions: erythromycin 735.5 (M+) → 577.5 (M+); 
clarithromycin 748.5 (M+) → 590.3 (M+); roxithromycin 
837.8 (M+) → 678.5 (M+); azithromycin 749.5 (M+) → 
591.5 (M+); telithromycin 407.5 (M++) → 656.1 (M+); 
warfarin 309.1(M+) → 163.3 (M+); propranolol 260.2 
(M+) → 116.2 (M+); testosterone 289.3 (M+) → 97.2 
(M+) and amprenavir 506 (M+) → 245.3 (M+). Samples 
from PAMPA, Caco-2 and MDCKII-hMDR1 studies 
were prepared by deproteinization with 3 volumes of 
acetonitrile:methanol (φ = 0.67) containing internal 
standard (clarithromycin or roxithromycin). There-
after, samples were centrifuged (4000 rpm, 15 min,  
4 °C) and an aliquot of supernatant was injected for 
analysis. 
Each tested substance sequence consisted of one 
calibration curve and samples. Calibration curves were 
designed to cover possible ranges of analyte concentra-
tions in matrix: a) 11 dilutions in range of 0.195–200 
μmol dm–3 for all tested substances in PAMPA; b) 10 
dilutions in ranges of 0.1–50 μmol dm–3 and 0.2–100 
μmol dm–3 for all tested macrolides and propranolol,  
respectively, in Caco-2 assay; and c) 12 dilutions in ranges 
of 0.0048–10 μmol dm–3 and 0.48 nmol dm–3–1 μmol dm–3 
for all tested macrolides and amprenavir, respectively, 
in MDCKII-hMDR1 assay. Linear regression analysis 
with 1/x or 1/x2 weighing factor was chosen as the most 
appropriate to determine the substance calibration 
curves. The correlation coefficient in each calibration 
curve was higher than 0.95. All back calculated values 
used within each selected calibration curve were below 
20 % of deviation. Peak areas of analyte and calibration 
curves were determined using the Analyst software 
version 1.4 (Applied Biosystems, Foster City, CA, 
USA). Other calculations were performed in MS Excel 
spreadsheet. 
 
RESULTS 
Papp values in PAMPA, obtained at pH = 7.4 with incu-
bation time of 3 h at room temperature (≈ 23 °C), are 
 
 
Figure 2. The apparent permeability coefficients (Papp/nm s–1) 
in PAMPA at pH = 7.4 obtained by incubating tested substances 
either for 3 or 24 h at room temperature (≈ 23 °C). Data is pre-
sented as mean value ± standard deviation from two replicates. 
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displayed in Figure 2. The apparent permeability for 
telithromycin could not be determined as the levels were 
below the lower limit of quantification (0.195 µmol dm–3). 
The highest PAMPA Papp values were obtained for cla-
rithromycin, indicating high permeability, followed by 
roxithromycin (moderate permeability), and low perme-
able azithromycin and erythromycin. 
The influence of time on passive diffusion was ex-
amined by prolonging the incubation time from 3 to 24 
h (Figure 2).16 For low permeable macrolides erythro-
mycin, azithromycin and telithromycin, no substantial 
differences in permeability with time were observed. 
Moreover, an increase in incubation time did not contri-
bute to an increase in telithromycin levels in the accep-
tor compartment significantly. For moderately perme-
able roxithromycin and highly permeable clarithro-
mycin an increase in incubation time resulted in 1.8- 
and 2.9-fold decreases in PAMPA Papp, respectively, 
which classifies clarithromycin from highly to mode-
rately permeable. Although prolonging the incubation 
time produces different results, no significant change 
was observed in the ranking of tested macrolides. 
Caco-2 Papp values were determined for both di-
rections, AB and BA, and together with the respective 
efflux ratio [Pappratio(BA/AB)] are listed in Table 1. 
Erythromycin26 and azithromycin showed very low AB 
permeability with Papp(AB) of 0.9 and 2.2 nm s–1, re-
spectively, in comparison to the more permeable macro-
lides, roxithromycin (5.2 nm s–1), telithromycin (19.4 
nm s–1) and clarithromycin (38.4 nm s–1). The addition 
of verapamil (Table 1), resulted in increased Papp values 
in the AB direction and in reduced Papp values in the BA 
direction, respectively in all cases with the exception of 
roxithromycin [Papp(BA) is 110.9 and 188.3 nm s–1 
without and with P-gp inhibition, respectively]. Caco-2 
efflux ratios with inhibited P-gp are significantly lower, 
from 1 to 2.8, than without P-gp inhibition. The TEER 
values varied slightly among different sets of plates and 
only monolayers with TEER ≥ 300 Ω were used in 
transport studies. 
The effect of pH gradient, more precisely the ef-
fect of apical pH, on Caco-2 permeability was deter-
mined using pH = 6.5 and 7.4 solutions in apical com-
partment and pH = 7.4 solution in the basolateral com-
partment. Papp in both directions, AB and BA, and their 
efflux ratio, are displayed in Figures 3a–c. While ery-
Table 1. The apparent permeabilities (Papp/nm s–1)* in Caco-2 cell assay from apical-to-basolateral (AB) and basolateral-to-apical 
(BA) side on pH = 7.4 without and with inhibition of P-glycoprotein (P-gp) efflux pump by verapamil. The ratios between Papp in 
BA and AB directions, [Pappratio(BA/AB)] 
Substance 
Noninhibited P-gp Inhibited P-gp 
app
–1
(AB)
nm s
P
 app –1
(BA)
nm s
P
 Pappratio(BA/AB) app –1
(AB)
nm s
P
 app –1
(BA)
nm s
P
 Pappratio(BA/AB)
erythromycin 0.9  0.2 63.8  3.3 74.5 4.4  0.2 11.6  1.4 2.6 
clarithromycin 38.4  4 183.3  6.5 4.8 72.9  1.8 73.4  5.8 1.0 
roxithromycin 5.2  1.2 110.9  9.1 21.3 86.9  5.4 188.3  5.6 2.2 
azithromycin 2.2  1.3 166.4  13.1 75 16.8  4.3 16.5  3.3 1.0 
telithromycin 19.4  2.2 94.9  2.3 4.9 26.8  2.7 75.6  0.4 2.8 
propanolol 121.8  4.5 94.2  3.1 0.8 127.2  4.1 80.6  1.4 0.6 
* data is presented as mean value ± standard deviation from three replicates. 
 
 
Figure 3. Effect of apical pH on the permeability of macrolides in Caco-2 cell assay. The apparent permeabilities (Papp/nm s–1) in a)
apical-to-basolateral (AB) direction, Papp(AB), b) in basolateral-to-apical (BA) direction, Papp(BA), and c) the ratio between Papp in BA
and AB directions [Pappratio(BA/AB)] obtained with (pH = 6.5 and 7.4 in apical and basolateral compartments, respectively) and without
pH gradient (pH = 7.4 in both compartments). Data is presented as mean value ± standard deviation from three replicates. 
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thromycin and azithromycin exhibit decreased permea-
bilities at lower apical pH, the other three macrolides 
showed an increased permeability (Figure 3c). The 
changes in efflux ratios are primarily caused by a de-
crease in Papp(AB) at lower apical pH, observed for all 
tested substances with the exception of azithromycin 
(Figure 3a). On the contrary, at lower pH, a relatively 
small decrease in Papp(BA) was observed for all but 
roxithromycin (Figure 3b). 
Papp values and the efflux ratios obtained in the 
MDCKII-hMDR1 assay, with and without P-gp inhibi-
tion by GF120918A, are listed in Table 2. Although 
Papp(AB) values for all five tested substances indicate 
low to moderate permeability, as observed in the Caco-2 
assay, the overall ranking differs. Clarithromycin, roxi-
thromycin and telithromycin exhibit low transport in the 
AB direction (3.3, 3.7, and 4.7 nm s–1, respectively), 
whereas erythromycin (10.1 nm s–1) and azithromycin 
(25.9 nm s–1) exhibit higher transport. Upon P-gp inhibi-
tion with GF120918A, Papp(AB) was increased for all 
macrolides except erythromycin where the change was 
negligible. Substantial increases in AB permeability 
were observed for clarithromycin and telithromycin with 
Papp(AB) of 54.1 and 59.3 nm s–1, respectively. Permea-
bility in BA direction was reduced by P-gp inhibition 
from 2 to 3.5 times for all of them. MDCKII-hMDR1 
efflux ratios were significantly lower upon P-gp inhi-
bition for all tested substances. 
 
DISCUSSION 
Transport studies using PAMPA, Caco-2 and MDCKII-
hMDR1 assays were performed for a set of five com-
mercially available macrolide drugs: 14-membered ring 
macrolides erythromycin, clarithromycin, and roxithro-
mycin, 15-membered ring macrolide azithromycin, and 
for a novel class representative, ketolide, 14-membered 
ring macrolide telithromycin. 
PAMPA Papp describes the affinity of compounds 
for transcellular passive diffusion in a system lacking 
active and paracellular transport. The macrolides tested 
are all weak bases with a protonated amine on the deso-
samine moiety at pH = 7.4. In addition, azithromycin 
has the protonated nitrogen in the macrolide ring at the 
same pH. Consequently, as being protonated at pH = 7.4, 
the tested substances showed relatively low PAMPA 
permeability. Our results, obtained after 3 h of incu-
bation, classify erythromycin and azithromycin as low 
permeable substances with the PAMPA Papp of 1.4 and 
13.1 nm s–1, respectively (Figure 2). Moderately perme-
able roxithromycin and clarithromycin showed signifi-
cantly higher PAMPA Papp (65.5 and 109.9 nm s–1, 
respectively). These results are in line with their higher 
oral bioavailability in humans (72–85 % and 55 %, 
respectively)19 in comparison to erythromycin and azith-
romycin (20 % and 37 %, respectively).19,35 Although 
they share similar physicochemical properties,36 a rela-
tively small structural difference between erythromycin 
and clarithromycin (hydroxy- vs. methoxy-substituent 
on the C6 position, respectively) causes a significant 
difference (79-fold increase) in their PAMPA permea-
bility. 
Although prolonging the incubation time from 3 to 
24 h, did not significantly change the overall ranking of 
tested substances, decreases in Papp values were ob-
served for clarithromycin and roxithromycin. Decreased 
Papp values could be explained by an increase of tested 
substance concentration in the acceptor compartment 
which comes closer to the theoretical equilibrium con-
centration ([substance]eq in Equation 1). Moreover, the 
PAMPA assay classifies telithromycin as nonpermeable 
as the concentrations of telithromycin were below the 
lower limit of quantification after 3 h of incubation. 
However, data from literature demonstrate that telith-
romycin has a good oral bioavailability in humans, very 
similar to clarithromycin (57 vs. 55 %, respectively).19,21 
In both cellular assays, Caco-2 and MDCKII-
hMDR1, permeability measurements are made in the 
Table 2. The apparent permeabilities (Papp/nm s–1)* in MDCKII-hMDR1 cell assay from apical-to-basolateral (AB) and baso-
lateral-to-apical (BA) side on pH = 7.4 without and with inhibition of P-glycoprotein (P-gp) efflux pump by GF120918A. The 
ratios between Papp in BA and AB directions, [Pappratio(BA/AB)] 
Substance 
Noninhibited P-gp Inhibited P-gp 
app
–1
(AB)
nm s
P
 app –1
(BA)
nm s
P
 Pappratio(BA/AB) app –1
(AB)
nm s
P
 app –1
(BA)
nm s
P
 Pappratio(BA/AB)
erythromycin 10.1 ± 0.3 128.7 ± 8.7 12.7 9.7 ± 0.4 62.6 ± 16.4 6.4 
clarithromycin 3.3 ± 0.9 548.6 ± 42.2 166 54.1 ± 3.2 159.1 ± 15.3 2.9 
roxithromycin 3.7 ± 0.4 298 ± 7.5 80 6.2 ± 0.9 98.5 ± 14.5 16 
azithromycin 25.9 ± 4.3 109.7 ± 18.7 4.2 35.9 ± 0.1 48.2 ± 9.9 1.3 
telithromycin 4.7 ± 0.8 358.5 ± 16.6 75.6 59.3 ± 13.4 151.6 ± 42.1 2.6 
propanolol 43.7 ± 7.5 738.2 ± 9.9 16.9 284.8 ± 11.9 537.5 ± 34.4 1.9 
* data is presented as mean value ± standard deviation from three replicates. 
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apical-to-basolateral and basolateral-to-apical directions 
with the apical side representing the gut lumen and the 
basolateral side representing the systemic circulation. 
The Caco-2 cell monolayer model mimics not only 
transcellular passive diffusion, as PAMPA, but also 
includes active transport, efflux and paracellular trans-
port. However, due to macrolide size (Mr > 700), para-
cellular transport can be neglected in this study. The 
influence of the pH gradient on the Caco-2 permeability 
for tested macrolides is not straightforward (Figure 3). 
Based on our results, the pH seems to affect not only the 
passive diffusion but could also affect the affinity of 
macrolides to behave as substrates for various efflux 
pumps and/or transporters.  
In the Caco-2 assay performed at pH = 7.4, all 
tested macrolides showed lower permeability in the AB 
direction in comparison to the BA direction (Table 1). 
Moreover, erythromycin and azithromycin showed a 
higher efflux ratios (74.5 and 75, respectively), when 
compared to same values obtained for roxithromycin 
(21.3), but especially for clarithromycin and telithromy-
cin (4.8 and 4.9, respectively). Differences in AB per-
meabilities are likely due to different affinities for the  
P-gp efflux system for the macrolides tested. It could be 
postulated that transport of erythromycin and azithro-
mycin is more influenced by active secretion and efflux 
system than other three macrolides. 
As previously reported in the literature, a compari-
son of efflux ratio generated in the presence and ab-
sence of a P-gp inhibitor (i.e. verapamil) is the method 
of choice in identifying P-gp substrates.2 A compound is 
typically considered to be a P-gp substrate when the 
efflux ratio in the absence of inhibitor is greater than 2 
and is at least halved in the presence of inhibitor.3 
Moreover, inhibition of P-gp by verapamil generally 
increased AB and decreased BA permeability.26 Accor-
dingly, erythromycin, clarithromycin, roxithromycin, 
and azithromycin could be classified as P-gp substrates 
(Table 1). On the other hand, telithromycin does not 
fulfil the second criteria, as efflux ratio decreased for 42 % 
by P-gp inhibition. However, this result is in accordance 
with previous findings in the literature that showed a 
much lower extent of P-gp involvement in the overall 
transport of telithromycin than for other macrolides.25  
It has been proposed that a change in efflux ratio in the 
presence of verapamil suggests that the greatest  
decrease in efflux ratio is indicative of the lowest rela-
tive apparent affinity for P-gp.25 According to our  
results obtained in the Caco-2 assay, the apparent P-gp 
affinity is in following order: azithromycin < erythro-
mycin < roxithromycin < clarithromycin < telithro-
mycin. 
One of the drawbacks of applied bidirectional 
permeability Caco-2 assay is the fact that other transpor-
ters, uptake/efflux proteins and metabolic enzymes are 
also functionally expressed in Caco-2 cells, therefore 
ranking of analysed macrolides according to their P-gp 
affinity could be ambiguous, at least. It raised the need 
to perform comparable experiments using MDCKII-
hMDR1 cell line with overexpression of human P-gp, 
low expression levels of other transporter proteins and 
low metabolic activity, in comparison to Caco-2 cells. 
Our results show that MDCKII-hMDR1 permea-
bility in AB direction is much lower than in the BA 
direction for all tested macrolides (Table 2), which is in 
line with data from the Caco-2 assay. However, the 
observed permeabilities in the BA direction are gener-
ally higher in MDCKII-hMDR1 than in the Caco-2 
assay. MDCKII-hMDR1 efflux ratios range from 4.2 to 
166, due to different and in some cases very low AB 
permeabilities. These results suggest a significant influ-
ence of the efflux mechanism on the permeability of 
tested macrolides in MDCKII-hMDR1 assay, especially 
in the cases of clarithromycin (166), roxithromycin (80), 
and telithromycin (75.6). Differences in the permeabili-
ty observed between Caco-2 and MDCKII-hMDR1 
assays could be result of the difference in the relative 
expression levels of total P-gp in each of them. Impor-
tantly, there is no data in literature that showed expres-
sion levels of P-gp or any transporters in MDCK cells 
and this should be taken into account when interpreting 
results of this assay. 
The potency of P-gp inhibition in MDCKII-
hMDR1 cells was assessed using verapamil and 
GF120918A in the same experimental set-up (data not 
shown). In these studies GF120918A demonstrated the 
same inhibitory potency at a 25 times lower concentra-
tion and was therefore used for further studies. P-gp 
inhibition with GF120918A in MDCKII-hMDR1 cells 
reduced the amount of tested substance transported from 
the cell to the apical side, thereby affecting the permea-
bility in both directions: increasing Papp(AB) and de-
creasing Papp(BA) for all tested macrolides, but erythro-
mycin. Interestingly, inhibition of P-gp with GF120918A 
resulted in a decreased transport of erythromycin in the 
BA direction, however, failed to influence its transport 
in the AB direction. Similar effects have been reported 
in the literature.25 Comparison of efflux ratio with and 
without P-gp inhibition reveals a significant decrease 
caused by P-gp inhibition, from 49 % for erythromycin 
to 98 % for clarithromycin, classifying all these macro-
lides as P-gp substrates. 
 
CONCLUSION 
Our data demonstrate that the tested set of macrolides 
behave as low to moderately permeable substances in all 
three assays used. Results obtained in cellular assays, 
Caco-2 and MDCKII-hMDR1, indicate involvement of 
active transport by being P-gp substrates. In order to 
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assess the impact of P-pg efflux activity on the oral 
absorption, in vivo studies in P-gp-deficient mice should 
be considered. Based on our results we can conclude 
that permeabilities obtained by PAMPA do not correlate 
with values obtained in both cellular assays and that this 
method is not appropriate for routine permeability 
screening of macrolides, as it only takes into account 
passive transport and likely inaccurately estimates the 
intrinsic permeability. 
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SAŽETAK  
Utvrđivanje transporta makrolida putem PAMPA, Caco-2  
i MDCKII-hMDR1 testova 
Danijela Nožinić,a Astrid Milić,a Lara Mikac,b Jovica Ralić,a Jasna Padovan,a 
i Roberto Antolovićc 
aGlaxoSmithKline centar za istraživanje Zagreb, Ltd., Prilaz baruna Filipovića 29, 10000 Zagreb, 
Croatia 
bZavod za fiziku materijala, Institut Ruđer Bošković, Bijenička 54, 10000 Zagreb, Croatia  
cOdjel za biotehnologiju, Sveučilište u Rijeci, S. Krautzeka bb, 51000 Rijeka, Croatia 
Transport komercijalnih makrolidnih antibiotika eritromicina, klaritromicina, roksitromicina, azitromicina i teli-
tromicina proučavan je PAMPA testom pasivne difuzije te Caco-2 i MDCKII-hMDR1 testovima aktivnog trans-
porta molekula kroz membranu. Proučavan je i utjecaj membranskog transportera P-glikoproteina (P-gp) na trans-
port makrolida. U Caco-2 i MDCKII-hMDR1 testovima bez P-gp inhibicije opažena je smanjena permeabilnost 
(Papp) iz apikalne prema bazolateralnoj (AB) nego li iz bazolateralne prema apikalnoj strani (BA) membrane  
[omjer permeabilnosti, Pappratio(BA/AB) > 4,2]. Uslijed P-gp inhibicije Papp(AB) se povećala, dok se Papp(BA) 
smanjila. Opažene Papp vrijednosti, omjeri permeabilnosti, kao i značajno smanjenje istih omjera uzrokovano P-gp 
inhibicijom (> 50 %), svrstava ovdje testirane makrolide u P-gp supstrate. Rezultati dobiveni PAMPA testom 
upućuju na zaključak da ovaj model nije dobar izbor za razvrstavanje makrolida prema njihovoj permeabilnosti, 
kako radi nepostojanja P-gp tako i/ili radi nepostojanja drugih transportera potencijalno uključenih u transport  
makrolida. 
